Trial reportCancer immunology, immunotherapy : CII2018
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Registry-linked trialAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph
Trial report in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00590824 (A Pilot Trial of HU14.18-IL2), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neoadjuvant treatment for stage III and IV cutaneous melanoma.The Cochrane database of systematic reviews · 2023Pooled it
- Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances.Journal of hematology & oncology · 2026Review
- Deciphering the role of glycolipids as emerging therapeutic targets in EMT-driven cancer progression.Discover oncology · 2026Review
- Immunocytokines in cancer: a safety perspective.Frontiers in immunology · 2026Review
- Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.Advances in experimental medicine and biology · 2026Review
- Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- The application of antibody-based agents in cancer therapy based on their mechanisms of action.Fundamental research · 2025Review
- Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein.Journal for immunotherapy of cancer · 2025Article
- Article
- Natural killer cell-based cancer immunotherapy: from basics to clinical trials.Experimental hematology & oncology · 2024Review
- Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.Pharmaceutics · 2024Review
- Intratumoral injection and retention hold promise to improve cytokine therapies for cancer.Frontiers in oncology · 2024Article
- Advances in engineering and delivery strategies for cytokine immunotherapy.Expert opinion on drug delivery · 2023Article
- The present and future of immunocytokines for cancer treatment.Cellular and molecular life sciences : CMLS · 2022Review
- Natural Killer Cell-Mediated Immunotherapy for Leukemia.Cancers · 2022Review
- The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.Cellular & molecular immunology · 2022Review
- Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy.Immune network · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Mark R AlbertiniUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. mralbert@wisc.edu.
Richard K YangDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Erik A RanheimUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Jacquelyn A HankUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Cindy L ZulegerUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Sharon WeberUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Heather NeumanUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Greg HartigUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Tracey WeigelWestchester Medical Center, New York Medical College, Valhalla, New York, USA.
David MahviDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.
Mary Beth HenryDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Renae QualeUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Thomas McFarlandUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Jacek GanUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Lakeesha CarmichaelDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
KyungMann KimUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Hans LoibnerApeiron Biologics AG, Vienna, Austria.
Stephen D GilliesProvenance Biopharmaceuticals Corp., Carlisle, MA, USA.
Paul M SondelUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6MUniversity of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9MInstitutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2MINTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MTHE IMMUNOBIOLOGY OF HUMAN ANTILEUKEMIC LYMPHOCYTESR01CA032685 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 1985 to 2014
$4.3MT-Cell Independent Antitumor Mechanisms of CD40 LigationR01CA087025 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2002 to 2012
$2.4MThe Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 ImmunotherapyR01CA166105 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2012 to 2014
$987kNCATS NIH HHS UL1 TR000427NCATS NIH HHS UL1TR000427NCATS NIH HHS UL1 TR002373NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA032685NCI NIH HHS R01 CA087025NCI NIH HHS R01 CA166105NCI NIH HHS R35 CA166105NCI NIH HHS R35 CA197078NIGMS NIH HHS T32 GM008692
Abstract
Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m
Indexed as
AdultAgedAntibodies, MonoclonalFemaleFollow-Up StudiesHumansInterleukin-2Lymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPilot ProjectsSurvival RateTumor BurdenAntibodies, MonoclonalInterleukin-2lorukafusp alfaAnti-ganglioside antibodyImmunocytokineImmunotherapyInterleukin-2Melanoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT00590824ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.